Rubella (German Measles)¶
Chapter 212 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Rubella is a viral infection caused by Rubella virus (family Matonaviridae), with congenital rubella syndrome (CRS) as a major complication.
- Vaccination with rubella-containing vaccines (RCV) has reduced global rubella cases by >99% since 1969, but importations and susceptible populations persist.
- CRS is associated with severe birth defects (e.g., cataracts, hearing loss, heart defects) and lifelong disabilities, with 90% risk if maternal infection occurs in first 10 weeks of pregnancy.
- Diagnosis requires serologic testing (IgM/IgG) and viral RNA detection, with IgM testing contraindicated in pregnant women without exposure history.
- Post-exposure immunoglobulin may reduce but not eliminate rubella risk, and RCV is contraindicated in pregnancy due to theoretical fetal transmission risk.
1. DEFINITION & OVERVIEW¶
Rubella is a viral illness caused by Rubella virus, characterized by a mild rash and lymphadenopathy. Congenital rubella syndrome (CRS) results from maternal infection during pregnancy, causing severe fetal malformations. The virus is transmitted via respiratory droplets and is preventable through vaccination.
Table 212-1: Common Transient and Permanent Manifestations in Infants with Congenital Rubella Syndrome¶
| TRANSIENT MANIFESTATIONS | PERMANENT MANIFESTATIONS |
|---|---|
| Hepatosplenomegaly | Hearing impairment/deafness |
| Interstitial pneumonitis | Congenital heart defects (patent ductus arteriosus, pulmonary arterial stenosis) |
| Thrombocytopenia with purpura/petechiae (e.g., dermal erythropoiesis or 'blueberry muffin syndrome') | Eye defects (cataracts, cloudy cornea, microphthalmos, pigmentary retinopathy, congenital glaucoma) |
| Hemolytic anemia | Microcephaly |
| Bony radiolucencies | Central nervous system sequelae (mental and motor delay, autism) |
| Intrauterine growth retardation | |
| Adenopathy | |
| Meningoencephalitis |
1.1 Historical Context¶
Historically viewed as a variant of measles, rubella was first recognized as a distinct entity in 1962. The 1964–1965 U.S. epidemic (12.5 million cases) highlighted the severity of CRS, leading to global vaccination programs.
1.2 Global Impact¶
Global rubella cases declined from ~700,000 in 2000 to 17,407 in 2022. CRS remains a public health concern, with 105,000 annual cases globally. Vaccination coverage remains <90% in 25% of countries.
2. EPIDEMIOLOGY¶
The largest U.S. rubella epidemic occurred 1964–1965 (12.5 million cases). Post-vaccination, annual cases dropped >99%. In 2022, 66 rubella cases were reported in the U.S., with 71% in 20–49-year-olds. CRS cases declined from ~20,000 annually pre-vaccination to 13 cases in 2010–2022.
2.1 Risk Factors¶
Unvaccinated individuals, pregnant women, and those in congregate settings (e.g., healthcare workers) are at highest risk. CRS risk peaks in first 10 weeks of gestation.
2.2 Demographics¶
CRS is most common in infants born to mothers infected during early pregnancy. In 2022, 25% of children globally remained unvaccinated.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Rubella virus (family Matonaviridae) is a single-stranded RNA enveloped virus (40–80 nm). Humans are the sole reservoir. Transmission occurs via respiratory droplets. Fetal infection leads to chronic infection, with virus replicating in placental tissues and causing multi-organ damage.
3.1 Viral Structure¶
The virus has a 10-kb positive-sense RNA genome enclosed in a protein shell and lipid envelope with E1/E2 glycoproteins. Only one antigenic type exists.
3.2 Pathogenesis¶
Primary infection replicates in nasopharynx, spreads to lymph nodes, and causes viremia. In pregnancy, placental transfer leads to fetal infection, with persistent viral replication causing organ-specific damage.
4. CLINICAL FEATURES¶
Acquired rubella presents with a mild maculopapular rash, lymphadenopathy, and arthralgia. Congenital rubella syndrome (CRS) causes severe birth defects, including cataracts, hearing loss, and heart defects. The classic triad of CRS includes cataracts, hearing impairment, and heart defects in ~10% of cases.
4.1 Acquired Rubella¶
Common symptoms include fever, malaise, and a 1–5-day prodrome. Rash typically lasts 3 days and is more prominent in younger children. Arthralgia and arthritis are common in adults.
4.2 Congenital Rubella Syndrome¶
CRS is characterized by multi-system defects, including microcephaly, intrauterine growth retardation, and central nervous system sequelae. Hearing loss is the most common single defect.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include measles, fifth disease, roseola, toxoplasmosis, and Zika virus. Key differentiators include the absence of high fever in rubella and the presence of lymphadenopathy.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis requires serologic testing (IgM/IgG) and viral RNA detection. For congenital infection, IgM is present for up to 6 months, while IgG avidity testing distinguishes recent vs. past infection.
Table 212-1: Common Transient and Permanent Manifestations in Infants with Congenital Rubella Syndrome¶
| TRANSIENT MANIFESTATIONS | PERMANENT MANIFESTATIONS |
|---|---|
| Hepatosplenomegaly | Hearing impairment/deafness |
| Interstitial pneumonitis | Congenital heart defects (patent ductus arteriosus, pulmonary arterial stenosis) |
| Thrombocytopenia with purpura/petechiae (e.g., dermal erythropoiesis or 'blueberry muffin syndrome') | Eye defects (cataracts, cloudy cornea, microphthalmos, pigmentary retinopathy, congenital glaucoma) |
| Hemolytic anemia | Microcephaly |
| Bony radiolucencies | Central nervous system sequelae (mental and motor delay, autism) |
| Intrauterine growth retardation | |
| Adenopathy | |
| Meningoencephalitis |
6.1 Serologic Testing¶
IgM detection via ELISA is most accurate. A fourfold rise in IgG titer confirms acute infection. IgG avidity testing helps differentiate recent vs. past infection.
6.2 Viral Detection¶
RT-PCR detects viral RNA in nasopharyngeal swabs, throat swabs, or urine. Virus isolation is also used for confirmation.
7. MANAGEMENT & TREATMENT¶
No specific antiviral therapy exists. Symptomatic management includes antipyretics and analgesics. Prevention is critical, with RCV (RA27/3 strain) providing >95% seroconversion in ≥ 1-year-olds.
7.1 Post-Exposure Prophylaxis¶
Immunoglobulin (20 mL IV) may reduce risk if administered within 72 hours of exposure. Not recommended for pregnant women without exposure history.
7.2 Vaccination¶
Routine vaccination schedules: 1st dose at 12–15 months, 2nd dose at 4–6 years. Adults without immunity should receive RCV. Pregnancy should be avoided for 28 days post-vaccination.
8. PROGNOSIS & COMPLICATIONS¶
CRS causes lifelong disabilities, with medical costs exceeding $1.5 billion in the 1964–1965 U.S. epidemic. Prognosis is poor for infants with severe defects, with 90% risk of CRS if infected in first 10 weeks of gestation.
8.1 Long-Term Outcomes¶
CRS survivors may develop intellectual disability, hearing loss, or visual impairment. Early diagnosis and intervention improve outcomes.
8.2 Complications¶
Thrombocytopenia, encephalitis, and fetal demise are rare complications. CRS is associated with significant socioeconomic burden.
9. SPECIAL CONSIDERATIONS¶
Pregnant women should avoid rubella exposure. RCV is contraindicated in pregnancy due to theoretical fetal transmission risk. Post-exposure immunoglobulin may reduce risk but does not eliminate it.
9.1 Pregnancy¶
Maternal infection during first trimester causes 90% CRS risk. IgM testing is contraindicated in pregnant women without exposure history.
10. KEY POINTS & CLINICAL PEARLS¶
- Rubella vaccination prevents 99% of cases and CRS. 2. CRS is a major cause of congenital disabilities. 3. IgM testing is not recommended for pregnant women without exposure. 4. RCV is contraindicated in pregnancy. 5. Early diagnosis and intervention improve CRS outcomes.